ORPOF (OSE Immunotherapeutics) Asset Turnover: 0.01 (As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $3.36
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Asset Turnover?

OSE Immunotherapeutics ORPOF 41 Asset Turnover is 0.01 as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $3.36 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. OSE Immunotherapeutics's Revenue for the six months ended in Dec. 2025 was $1.52 Mil. OSE Immunotherapeutics's Total Assets for the quarter that ended in Dec. 2025 was $106.25 Mil. Therefore, OSE Immunotherapeutics's Asset Turnover for the quarter that ended in Dec. 2025 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. OSE Immunotherapeutics's annualized ROE % for the quarter that ended in Dec. 2025 was -116.41%. It is also linked to ROA % through Du Pont Formula. OSE Immunotherapeutics's annualized ROA % for the quarter that ended in Dec. 2025 was -49.78%.

OSE Immunotherapeutics  (OTCPK:ORPOF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

OSE Immunotherapeutics's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-52.89/45.4335
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-52.89 / 3.036)*(3.036 / 106.2505)*(106.2505/ 45.4335)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1742.09 %*0.0286*2.3386
=ROA %*Equity Multiplier
=-49.78 %*2.3386
=-116.41 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

OSE Immunotherapeutics's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-52.89/106.2505
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-52.89 / 3.036)*(3.036 / 106.2505)
=Net Margin %*Asset Turnover
=-1742.09 %*0.0286
=-49.78 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

OSE Immunotherapeutics Asset Turnover Related Terms

OSE Immunotherapeutics Asset Turnover Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Asset Turnover Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.18 0.03 0.67 0.03

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.62 0.01 0.01 0.01

ORPOF vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, OSE Immunotherapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OSE Immunotherapeutics Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Asset Turnover falls into.


ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

OSE Immunotherapeutics's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=3.067/( (129.8+92.338)/ 2 )
=3.067/111.069
=0.03

OSE Immunotherapeutics's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=1.518/( (120.163+92.338)/ 2 )
=1.518/106.2505
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.01 mean?
OSE Immunotherapeutics (ORPOF) has a Asset Turnover of 0.01 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Asset Turnover too high?
OSE Immunotherapeutics' current Asset Turnover is 0.01. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Asset Turnover compare to VRTX and REGN?
OSE Immunotherapeutics' Asset Turnover of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Asset Turnover is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.43 — trading 31.8% above its estimated fair value. The current Asset Turnover is 0.01. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Asset Turnover is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 31.8% above its estimated GF Value™ of $3.36. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Asset Turnover: 0.01
  • GF Value™: $3.36 vs. price of $4.43 (31.8% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$3.36
GF Value